Oral mizoribine pulse therapy for patients with steroid-resistant and frequently relapsing steroid-dependent nephrotic syndrome
Background. We investigated the efficacy of oral mizoribine pulse therapy (mizoribine-pulse) for cyclosporin (CyA)-dependent, steroid-resistant nephrotic syndrome (SRNS) and frequently relapsing, steroid-dependent nephrotic syndrome (FR-SDNS). Methods. One child with CyA-dependent SRNS and eight chi...
Gespeichert in:
| Veröffentlicht in: | Nephrology, dialysis, transplantation dialysis, transplantation, 2005-10, Vol.20 (10), p.2243-2247 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2247 |
|---|---|
| container_issue | 10 |
| container_start_page | 2243 |
| container_title | Nephrology, dialysis, transplantation |
| container_volume | 20 |
| creator | Kawasaki, Yukihiko Hosoya, Mitsuaki Kobayashi, Schogo Ohara, Shinichirou Onishi, Noriko Takahashi, Ai Isome, Masato Suzuki, Hitoshi |
| description | Background. We investigated the efficacy of oral mizoribine pulse therapy (mizoribine-pulse) for cyclosporin (CyA)-dependent, steroid-resistant nephrotic syndrome (SRNS) and frequently relapsing, steroid-dependent nephrotic syndrome (FR-SDNS). Methods. One child with CyA-dependent SRNS and eight children with CyA-dependent FR-SDNS were treated with mizoribine-pulse (daily dose: 10 mg/kg; maximum total dose 500 mg). We compared clinical manifestations before and after mizoribine-pulse, and studied the changes in serum mizoribine concentration in each patient on days when mizoribine was administered. Results. Four patients had no subsequent relapses (responders). Two of the four responders discontinued prednisolone and CyA, the other two discontinued CyA. Although each of the five other patients (non-responders) experienced single subsequent relapses, the dosages of prednisolone and CyA after mizoribine-pulse were decreased significantly compared with before mizoribine-pulse. The peak blood concentration of mizoribine in the responders was higher than in the non-responders (3.6±0.9 vs 1.8±0.4 µg/ml). Conclusions. Mizoribine-pulse may be effective for some patients with CyA-dependent SRNS and FR-SDNS. |
| doi_str_mv | 10.1093/ndt/gfh996 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68593244</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68593244</sourcerecordid><originalsourceid>FETCH-LOGICAL-c416t-1829bfb9c927d2e3f4b2e4385ed13683e5aacfcb33fd5d6ce434d332f6f335ac3</originalsourceid><addsrcrecordid>eNpd0cFu1DAQBmALgehSuPAAyEKCA1KonUmc-AgVUEpFOYCEuFiOPe66JE6wHcFy4dUx2lUrcfLh_zQe-yfkMWcvOZNwEmw-uXJbKcUdsuGNYFUNfXuXbErIK9YyeUQepHTNGJN1190nR1wwYAzkhvy5jHqkk_89Rz_4gHRZx4Q0bzHqZUfdHOmis8eQE_3p85amjHH2toqYfMo6ZKqDpS7ij7WgcUcjjnpJPlzdUIsLBltSGnDZxjl7Q9Mu2DhP-JDcc7rc-OhwHpMvb998Pj2rLi7fvT99dVGZhotc8b6WgxukKQ-wNYJrhhqb8kq0HEQP2GptnBkAnG2tMCVrLEDthANotYFj8nw_d4lz2TRlNflkcBx1wHlNSvSthLppCnz6H7ye1xjKbqrmPRctg76gF3tk4pxSRKeW6Ccdd4oz9a8TVTpR-04KfnKYuA4T2lt6KKGAZwegk9GjizoYn25dx9tSIhRX7V35ePx1k-v4XYkOuladff2mJP90_vrDx0adw19ESqhK</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>218165038</pqid></control><display><type>article</type><title>Oral mizoribine pulse therapy for patients with steroid-resistant and frequently relapsing steroid-dependent nephrotic syndrome</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Kawasaki, Yukihiko ; Hosoya, Mitsuaki ; Kobayashi, Schogo ; Ohara, Shinichirou ; Onishi, Noriko ; Takahashi, Ai ; Isome, Masato ; Suzuki, Hitoshi</creator><creatorcontrib>Kawasaki, Yukihiko ; Hosoya, Mitsuaki ; Kobayashi, Schogo ; Ohara, Shinichirou ; Onishi, Noriko ; Takahashi, Ai ; Isome, Masato ; Suzuki, Hitoshi</creatorcontrib><description>Background. We investigated the efficacy of oral mizoribine pulse therapy (mizoribine-pulse) for cyclosporin (CyA)-dependent, steroid-resistant nephrotic syndrome (SRNS) and frequently relapsing, steroid-dependent nephrotic syndrome (FR-SDNS). Methods. One child with CyA-dependent SRNS and eight children with CyA-dependent FR-SDNS were treated with mizoribine-pulse (daily dose: 10 mg/kg; maximum total dose 500 mg). We compared clinical manifestations before and after mizoribine-pulse, and studied the changes in serum mizoribine concentration in each patient on days when mizoribine was administered. Results. Four patients had no subsequent relapses (responders). Two of the four responders discontinued prednisolone and CyA, the other two discontinued CyA. Although each of the five other patients (non-responders) experienced single subsequent relapses, the dosages of prednisolone and CyA after mizoribine-pulse were decreased significantly compared with before mizoribine-pulse. The peak blood concentration of mizoribine in the responders was higher than in the non-responders (3.6±0.9 vs 1.8±0.4 µg/ml). Conclusions. Mizoribine-pulse may be effective for some patients with CyA-dependent SRNS and FR-SDNS.</description><identifier>ISSN: 0931-0509</identifier><identifier>EISSN: 1460-2385</identifier><identifier>DOI: 10.1093/ndt/gfh996</identifier><identifier>PMID: 16030039</identifier><identifier>CODEN: NDTREA</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Administration, Oral ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Anti-Inflammatory Agents - administration & dosage ; Anti-Inflammatory Agents - therapeutic use ; Biological and medical sciences ; Child ; Child, Preschool ; children ; clinical ; Cyclosporine - administration & dosage ; Cyclosporine - therapeutic use ; Drug Resistance ; Emergency and intensive care: renal failure. Dialysis management ; Female ; Glomerulonephritis ; Human viral diseases ; Humans ; Immunosuppressive Agents - administration & dosage ; Immunosuppressive Agents - adverse effects ; Immunosuppressive Agents - blood ; Immunosuppressive Agents - therapeutic use ; Infectious diseases ; Intensive care medicine ; Male ; Medical sciences ; mizoribine oral pulse therapy ; Nephrology. Urinary tract diseases ; Nephropathies. Renovascular diseases. Renal failure ; nephrotic syndrome ; Nephrotic Syndrome - blood ; Nephrotic Syndrome - drug therapy ; Prednisolone - administration & dosage ; Prednisolone - therapeutic use ; Recurrence ; Ribonucleosides - administration & dosage ; Ribonucleosides - adverse effects ; Ribonucleosides - blood ; Ribonucleosides - therapeutic use ; steroid-resistant nephrotic syndrome ; Viral diseases ; Viral diseases of the lymphoid tissue and the blood. Aids</subject><ispartof>Nephrology, dialysis, transplantation, 2005-10, Vol.20 (10), p.2243-2247</ispartof><rights>2005 INIST-CNRS</rights><rights>Copyright Oxford University Press(England) Oct 2005</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c416t-1829bfb9c927d2e3f4b2e4385ed13683e5aacfcb33fd5d6ce434d332f6f335ac3</citedby><cites>FETCH-LOGICAL-c416t-1829bfb9c927d2e3f4b2e4385ed13683e5aacfcb33fd5d6ce434d332f6f335ac3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17150503$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16030039$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kawasaki, Yukihiko</creatorcontrib><creatorcontrib>Hosoya, Mitsuaki</creatorcontrib><creatorcontrib>Kobayashi, Schogo</creatorcontrib><creatorcontrib>Ohara, Shinichirou</creatorcontrib><creatorcontrib>Onishi, Noriko</creatorcontrib><creatorcontrib>Takahashi, Ai</creatorcontrib><creatorcontrib>Isome, Masato</creatorcontrib><creatorcontrib>Suzuki, Hitoshi</creatorcontrib><title>Oral mizoribine pulse therapy for patients with steroid-resistant and frequently relapsing steroid-dependent nephrotic syndrome</title><title>Nephrology, dialysis, transplantation</title><addtitle>Nephrol. Dial. Transplant</addtitle><description>Background. We investigated the efficacy of oral mizoribine pulse therapy (mizoribine-pulse) for cyclosporin (CyA)-dependent, steroid-resistant nephrotic syndrome (SRNS) and frequently relapsing, steroid-dependent nephrotic syndrome (FR-SDNS). Methods. One child with CyA-dependent SRNS and eight children with CyA-dependent FR-SDNS were treated with mizoribine-pulse (daily dose: 10 mg/kg; maximum total dose 500 mg). We compared clinical manifestations before and after mizoribine-pulse, and studied the changes in serum mizoribine concentration in each patient on days when mizoribine was administered. Results. Four patients had no subsequent relapses (responders). Two of the four responders discontinued prednisolone and CyA, the other two discontinued CyA. Although each of the five other patients (non-responders) experienced single subsequent relapses, the dosages of prednisolone and CyA after mizoribine-pulse were decreased significantly compared with before mizoribine-pulse. The peak blood concentration of mizoribine in the responders was higher than in the non-responders (3.6±0.9 vs 1.8±0.4 µg/ml). Conclusions. Mizoribine-pulse may be effective for some patients with CyA-dependent SRNS and FR-SDNS.</description><subject>Administration, Oral</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Anti-Inflammatory Agents - administration & dosage</subject><subject>Anti-Inflammatory Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>children</subject><subject>clinical</subject><subject>Cyclosporine - administration & dosage</subject><subject>Cyclosporine - therapeutic use</subject><subject>Drug Resistance</subject><subject>Emergency and intensive care: renal failure. Dialysis management</subject><subject>Female</subject><subject>Glomerulonephritis</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Immunosuppressive Agents - administration & dosage</subject><subject>Immunosuppressive Agents - adverse effects</subject><subject>Immunosuppressive Agents - blood</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Infectious diseases</subject><subject>Intensive care medicine</subject><subject>Male</subject><subject>Medical sciences</subject><subject>mizoribine oral pulse therapy</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Nephropathies. Renovascular diseases. Renal failure</subject><subject>nephrotic syndrome</subject><subject>Nephrotic Syndrome - blood</subject><subject>Nephrotic Syndrome - drug therapy</subject><subject>Prednisolone - administration & dosage</subject><subject>Prednisolone - therapeutic use</subject><subject>Recurrence</subject><subject>Ribonucleosides - administration & dosage</subject><subject>Ribonucleosides - adverse effects</subject><subject>Ribonucleosides - blood</subject><subject>Ribonucleosides - therapeutic use</subject><subject>steroid-resistant nephrotic syndrome</subject><subject>Viral diseases</subject><subject>Viral diseases of the lymphoid tissue and the blood. Aids</subject><issn>0931-0509</issn><issn>1460-2385</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpd0cFu1DAQBmALgehSuPAAyEKCA1KonUmc-AgVUEpFOYCEuFiOPe66JE6wHcFy4dUx2lUrcfLh_zQe-yfkMWcvOZNwEmw-uXJbKcUdsuGNYFUNfXuXbErIK9YyeUQepHTNGJN1190nR1wwYAzkhvy5jHqkk_89Rz_4gHRZx4Q0bzHqZUfdHOmis8eQE_3p85amjHH2toqYfMo6ZKqDpS7ij7WgcUcjjnpJPlzdUIsLBltSGnDZxjl7Q9Mu2DhP-JDcc7rc-OhwHpMvb998Pj2rLi7fvT99dVGZhotc8b6WgxukKQ-wNYJrhhqb8kq0HEQP2GptnBkAnG2tMCVrLEDthANotYFj8nw_d4lz2TRlNflkcBx1wHlNSvSthLppCnz6H7ye1xjKbqrmPRctg76gF3tk4pxSRKeW6Ccdd4oz9a8TVTpR-04KfnKYuA4T2lt6KKGAZwegk9GjizoYn25dx9tSIhRX7V35ePx1k-v4XYkOuladff2mJP90_vrDx0adw19ESqhK</recordid><startdate>20051001</startdate><enddate>20051001</enddate><creator>Kawasaki, Yukihiko</creator><creator>Hosoya, Mitsuaki</creator><creator>Kobayashi, Schogo</creator><creator>Ohara, Shinichirou</creator><creator>Onishi, Noriko</creator><creator>Takahashi, Ai</creator><creator>Isome, Masato</creator><creator>Suzuki, Hitoshi</creator><general>Oxford University Press</general><general>Oxford Publishing Limited (England)</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>20051001</creationdate><title>Oral mizoribine pulse therapy for patients with steroid-resistant and frequently relapsing steroid-dependent nephrotic syndrome</title><author>Kawasaki, Yukihiko ; Hosoya, Mitsuaki ; Kobayashi, Schogo ; Ohara, Shinichirou ; Onishi, Noriko ; Takahashi, Ai ; Isome, Masato ; Suzuki, Hitoshi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c416t-1829bfb9c927d2e3f4b2e4385ed13683e5aacfcb33fd5d6ce434d332f6f335ac3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Administration, Oral</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Anti-Inflammatory Agents - administration & dosage</topic><topic>Anti-Inflammatory Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>children</topic><topic>clinical</topic><topic>Cyclosporine - administration & dosage</topic><topic>Cyclosporine - therapeutic use</topic><topic>Drug Resistance</topic><topic>Emergency and intensive care: renal failure. Dialysis management</topic><topic>Female</topic><topic>Glomerulonephritis</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Immunosuppressive Agents - administration & dosage</topic><topic>Immunosuppressive Agents - adverse effects</topic><topic>Immunosuppressive Agents - blood</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Infectious diseases</topic><topic>Intensive care medicine</topic><topic>Male</topic><topic>Medical sciences</topic><topic>mizoribine oral pulse therapy</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Nephropathies. Renovascular diseases. Renal failure</topic><topic>nephrotic syndrome</topic><topic>Nephrotic Syndrome - blood</topic><topic>Nephrotic Syndrome - drug therapy</topic><topic>Prednisolone - administration & dosage</topic><topic>Prednisolone - therapeutic use</topic><topic>Recurrence</topic><topic>Ribonucleosides - administration & dosage</topic><topic>Ribonucleosides - adverse effects</topic><topic>Ribonucleosides - blood</topic><topic>Ribonucleosides - therapeutic use</topic><topic>steroid-resistant nephrotic syndrome</topic><topic>Viral diseases</topic><topic>Viral diseases of the lymphoid tissue and the blood. Aids</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kawasaki, Yukihiko</creatorcontrib><creatorcontrib>Hosoya, Mitsuaki</creatorcontrib><creatorcontrib>Kobayashi, Schogo</creatorcontrib><creatorcontrib>Ohara, Shinichirou</creatorcontrib><creatorcontrib>Onishi, Noriko</creatorcontrib><creatorcontrib>Takahashi, Ai</creatorcontrib><creatorcontrib>Isome, Masato</creatorcontrib><creatorcontrib>Suzuki, Hitoshi</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Nephrology, dialysis, transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kawasaki, Yukihiko</au><au>Hosoya, Mitsuaki</au><au>Kobayashi, Schogo</au><au>Ohara, Shinichirou</au><au>Onishi, Noriko</au><au>Takahashi, Ai</au><au>Isome, Masato</au><au>Suzuki, Hitoshi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Oral mizoribine pulse therapy for patients with steroid-resistant and frequently relapsing steroid-dependent nephrotic syndrome</atitle><jtitle>Nephrology, dialysis, transplantation</jtitle><addtitle>Nephrol. Dial. Transplant</addtitle><date>2005-10-01</date><risdate>2005</risdate><volume>20</volume><issue>10</issue><spage>2243</spage><epage>2247</epage><pages>2243-2247</pages><issn>0931-0509</issn><eissn>1460-2385</eissn><coden>NDTREA</coden><abstract>Background. We investigated the efficacy of oral mizoribine pulse therapy (mizoribine-pulse) for cyclosporin (CyA)-dependent, steroid-resistant nephrotic syndrome (SRNS) and frequently relapsing, steroid-dependent nephrotic syndrome (FR-SDNS). Methods. One child with CyA-dependent SRNS and eight children with CyA-dependent FR-SDNS were treated with mizoribine-pulse (daily dose: 10 mg/kg; maximum total dose 500 mg). We compared clinical manifestations before and after mizoribine-pulse, and studied the changes in serum mizoribine concentration in each patient on days when mizoribine was administered. Results. Four patients had no subsequent relapses (responders). Two of the four responders discontinued prednisolone and CyA, the other two discontinued CyA. Although each of the five other patients (non-responders) experienced single subsequent relapses, the dosages of prednisolone and CyA after mizoribine-pulse were decreased significantly compared with before mizoribine-pulse. The peak blood concentration of mizoribine in the responders was higher than in the non-responders (3.6±0.9 vs 1.8±0.4 µg/ml). Conclusions. Mizoribine-pulse may be effective for some patients with CyA-dependent SRNS and FR-SDNS.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>16030039</pmid><doi>10.1093/ndt/gfh996</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0931-0509 |
| ispartof | Nephrology, dialysis, transplantation, 2005-10, Vol.20 (10), p.2243-2247 |
| issn | 0931-0509 1460-2385 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68593244 |
| source | MEDLINE; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Administration, Oral Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Anti-Inflammatory Agents - administration & dosage Anti-Inflammatory Agents - therapeutic use Biological and medical sciences Child Child, Preschool children clinical Cyclosporine - administration & dosage Cyclosporine - therapeutic use Drug Resistance Emergency and intensive care: renal failure. Dialysis management Female Glomerulonephritis Human viral diseases Humans Immunosuppressive Agents - administration & dosage Immunosuppressive Agents - adverse effects Immunosuppressive Agents - blood Immunosuppressive Agents - therapeutic use Infectious diseases Intensive care medicine Male Medical sciences mizoribine oral pulse therapy Nephrology. Urinary tract diseases Nephropathies. Renovascular diseases. Renal failure nephrotic syndrome Nephrotic Syndrome - blood Nephrotic Syndrome - drug therapy Prednisolone - administration & dosage Prednisolone - therapeutic use Recurrence Ribonucleosides - administration & dosage Ribonucleosides - adverse effects Ribonucleosides - blood Ribonucleosides - therapeutic use steroid-resistant nephrotic syndrome Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids |
| title | Oral mizoribine pulse therapy for patients with steroid-resistant and frequently relapsing steroid-dependent nephrotic syndrome |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T01%3A15%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Oral%20mizoribine%20pulse%20therapy%20for%20patients%20with%20steroid-resistant%20and%20frequently%20relapsing%20steroid-dependent%20nephrotic%20syndrome&rft.jtitle=Nephrology,%20dialysis,%20transplantation&rft.au=Kawasaki,%20Yukihiko&rft.date=2005-10-01&rft.volume=20&rft.issue=10&rft.spage=2243&rft.epage=2247&rft.pages=2243-2247&rft.issn=0931-0509&rft.eissn=1460-2385&rft.coden=NDTREA&rft_id=info:doi/10.1093/ndt/gfh996&rft_dat=%3Cproquest_cross%3E68593244%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=218165038&rft_id=info:pmid/16030039&rfr_iscdi=true |